Quarterlytics / Healthcare / Medical - Distribution / Henry Schein / FY2008 Annual Report

Henry Schein
Annual Report 2008

HSIC · NASDAQ Healthcare
Claim this profile
Ticker HSIC
Exchange NASDAQ
Sector Healthcare
Industry Medical - Distribution
Employees 10,000+
← All annual reports
FY2008 Annual Report · Henry Schein
Loading PDF…
HELPINGHEALTHHAPPEN®

A N N U A L   R E P O R T   2 0 0 8

ABOUT THE COVER

During these times of economic 

uncertainty when healthcare practitioners

are facing new challenges and 

opportunities, Henry Schein is 

“helping health happen®” in all that 

we do – through the expert advice and

superior service we provide to our 

customers; the comprehensive selection

of technology-driven products and 

value-added services we offer; the 

unsurpassed efficiency and accuracy 

of our worldwide operations;

and the global, national and local 

healthcare issues we address through 

Henry Schein Cares.

quarksHKnew6  4/14/09  2:47 PM  Page 1

ABOUT HENRY SCHEIN

One of Henry Schein’s strengths is the 

Company’s centralized, leveragable infrastructure, 

which has capacity for additional growth.

enry Schein, Inc., a FORTUNE 500®

H
company and a member of the NASDAQ

business groups—Dental, Medical,

for healthcare professionals, such as

International and Technology—serve

ARUBA®, the Company’s electronic 

100® Index, is the largest distributor 

more than 575,000 healthcare practition-

catalog and ordering system. Its leading

of healthcare products and services 

ers worldwide, as well as governments

dental and medical practice-manage-

to office-based practitioners in the 

and other institutions providing health-

ment and electronic medical records

combined North American and European

care services. The Company operates

software solutions have an active user

markets. The Company has been 

named “Most Admired” in its industry 

in FORTUNE’s list of the World’s Most

Admired Companies, and number one 

in its industry in social responsibility for

five consecutive years.

through a centralized and automated 

distribution network, which provides 

customers in more than 200 countries

base of more than 60,000 practices.

Headquartered in Melville, New York,

with a comprehensive selection of more

Henry Schein employs more than 

than 90,000 national and Henry Schein

12,500 people and has operations or

brand products in stock, as well as 

affiliates in 23 countries. The Company’s

more than 100,000 additional products 

net sales reached a record $6.4 billion 

Henry Schein is recognized for its

available as special-order items.  

in 2008. For more information, 

excellent customer service and highly

Henry Schein also offers a wide range of

visit the Henry Schein Web site at 

competitive prices. The Company’s four

innovative value-added practice solutions

www.henryschein.com.

1

quarksHKnew6  4/14/09  2:47 PM  Page 2

FINANCIAL HIGHLIGHTS

NET SALES
from Continuing Operations

($ in Millions)

$7,000

$5,000

CAGR 14%*

$6,395

$5,904

$5,036

$4,526

$3,795

$3,000

$1,000

$0

$3.00

$2.00

$1.00

$0

2004

2005

2006

2007

2008

EARNINGS PER DILUTED SHARE
from Continuing Operations 

CAGR 21%*

$2.96

$2.59

$2.04

$1.70

$1.39

2004

2005

2006

2007

2008

*Compound Annual Growth Rate

OPERATING INCOME 
from Continuing Operations

($ in Millions) 

CAGR 21%*

$443

$388

$305

$262

$500

$400

$300

$200

$205

$100

$0

$400

$300

$200

$100

$0

2004

2005

2006

2007

2008

OPERATING CASH FLOW
AND CAPITAL EXPENDITURES

•

($ in Millions)

$385

$270

$255

$235

$183

$51

$38

$67

$57

$51

2004

2005

2006

2007

2008

NOTE:
Operating Income and Earnings Per Diluted Share from Continuing Operations have been adjusted to exclude certain 
one-time items. Refer to Non-GAAP Disclosures on page 8. Additionally, refer to our annual consolidated financial
statements for a complete presentation of our Consolidated Statements of Cash Flows.

2

quarksHKnew6  4/14/09  2:47 PM  Page 3

HENRY SCHEIN AT A GLANCE

DENTAL

MEDICAL

INTERNATIONAL

• Includes Henry Schein Dental (U.S.),

• Serves approximately 45% of the 

• Serves approximately 240,000 office-

TECHNOLOGY AND 

VALUE-ADDED SERVICES

Henry Schein Canada and Zahn Dental

estimated 250,000 U.S. office-based

based dental, medical and animal health

• Henry Schein Practice Solutions supports

Laboratory (U.S.) 

physician practices, as well as surgical

practices through operations or affiliates

dental clients and Henry Schein Medical

• Serves approximately 85% of the 

centers and other alternate-care sites

in 21 countries outside of North America  

Systems supports medical clients

estimated 136,000 U.S. and Canadian

• Offers approximately 32,000 medical

• Countries served are Australia, Austria,

• Practice management and electronic

office-based dental practices, dental 

products in stock and many more as

Belgium, China, the Czech Republic,

medical records systems active user

laboratories, as well as governments 

special-order items

France, Germany, Iceland, Ireland, Israel,

base of more than 60,000 dental,

Camlog™ dental implant system;

the American Academy of Ophthalmology 

Impianti (Dental, Italy); Medka (Medical,

American Academy of Dermatology, and

• Key 2008 acquisitions: DNA Anthos

and other institutions

• Leading supplier of medical consum-

• Offers approximately 46,000 

ables, a wide range of pharmaceuticals

in-stock products and many more 

and technology-driven equipment to

as special-order items

physicians and alternate-care sites

• Key product exclusives/semi-exclusives:

• Purchase plans provide for the American

E4D CAD/CAM restorative system;
Arestin® by Orapharma; Ortho
Organizers® orthodontic products;

Medical Association, the American

Society of Plastic Surgeons, the

Colgate® Oral Care Products; 

DEXIS® digital radiography products; 

i-CAT® 3-D Imaging Systems; 

BIOLASE® dental laser systems; 

KaVo; Noritake dental materials; 
Pelton & Crane; Pentron® Laboratory
Products; Gendex®; surgical instruments

from A. Titan Instruments; 

Snap-on Smile® restorative appliances; 

Shade-X™ and ShadeVision®

from X-Rite

• Key 2008 acquisition:

Ortho Organizers

• Key product exclusives/semi-exclusives:

Medline products and services for office-

based practitioners, Ambulatory Surgery

Centers and Integrated Delivery

Networks; Henry Schein Rx Samples

Service powered by MedManage™

ANIMAL HEALTH

• Serves approximately 75% of the 

estimated 27,000 U.S. animal health

practices

• Offers approximately 22,000 animal

health products in stock and many 

more as special-order items  

• Important new animal health product
introductions in 2008: Promeris® and
Vectra 3D™ topical flea and tick treat-

ments for dogs and cats; Comfortis™

monthly flea treatment pill; MyVetDirect

online pharmacy for home delivery of

prescriptions written by veterinarians

Italy, Luxembourg, the Netherlands,

medical and animal health practices

New Zealand, Portugal, Saudi Arabia,

Slovakia, Spain, Switzerland, the United

Arab Emirates, and the United Kingdom  

• Key products include: DENTRIX®,
Dental Vision, Oasis®, EXACT®,

and Easy Dental® for dental practices;

• Schein Direct provides direct air package

MicroMD® for medical providers 

delivery service to practitioners in more

in primary care and all major specialties;

than 200 countries around the world

LabNet® for dental laboratories; and

AVImark® for animal health practices

• Value-added services include: repair
services through ProRepair® and
COMPLETEcare; office design 

Germany); Noviko (Animal Health,

Czech Republic); ABC Group of

Companies (Dental, Hong Kong); 

services; continuing education for 

Minerva Dental (Dental, U.K.); 

Sirona Ibérica (Dental, Spain)

healthcare professionals; electronic

health claims processing (52 million

claims processed in 2008); Office

Automation Technology Solutions; 24/7
ordering capability through the ARUBA®
Web-based electronic catalog; and

Financial Services such as equipment

leasing and financing, patient financing,

and electronic credit card processing

2008 WORLDWIDE NET SALES
from Continuing Operations

$6.4 Billion

40% Dental 

22% Medical

35% International

3% Technology

3

quarksHKnew6  4/14/09  2:47 PM  Page 4

TO OUR STOCKHOLDERS

“Healthcare is 

historically 

more resistant to

macroeconomic 

challenges.”

B

y any measure, 2008 was a challenging year for corporations

Growth during 2008 continued to be enhanced by strategic

around the world, particularly those operating in the United

acquisitions, which included:  

States. Henry Schein was not immune to these challenges,

• Minerva Dental, a full-service dental distributor in the 

although our Company fared better than most. Healthcare is 

U.K., which strengthens our presence in the U.K. dental

historically more resistant to macroeconomic challenges. 

equipment market; 

Henry Schein is strategically and geographically diversified, 

operationally efficient and customer focused, making us more

resilient to these turbulent times. Our financial results for 2008

clearly illustrate this fact.

2008 Financial Results  

Our 2008 record net sales of $6.4 billion represent an increase

of 8.3% compared with 2007. This increase includes 7.5% 

• Noviko, the leading distributor of animal health supplies 

in the Czech Republic, the addition of which we believe

makes Henry Schein the largest Pan-European animal

health distributor; 

• DNA Anthos Impianti, which adds national equipment sales

and service capabilities to Henry Schein’s offering in Italy; 

local currency growth (1.3% internally generated and 6.2% from

• Medka, a full-service provider of medical consumables,

acquisitions) and 0.8% related to foreign currency exchange.

equipment and technical services in Germany, which 

Excluding sales of certain lower-margin pharmaceutical products

complements our current German operations; 

that we discontinued selling in 2008, internal net sales growth 

in local currencies was 3.6%.

• ABC Group of Companies, a Hong Kong-based dental

equipment and merchandise distributor that extends our

Our income from continuing operations for 2008 was 

presence in the growing Chinese dental market; 

$251.0 million, or $2.75 per diluted share. Excluding certain 

one-time charges1, income from continuing operations for 2008

was $270.0 million, or $2.96 per diluted share, reflecting growth

of 14.4% and 14.3%, respectively, compared with 2007.

Our operating margin excluding certain one-time charges for

2008 was 6.9%, an increase of 35 basis points, which is in line

with our stated Company goal for annual operating margin

expansion. We also generated record operating cash flow of

$384.6 million for the year.

4

• Sirona Ibérica, a distribution subsidiary of Sirona Dental

Systems, which enhances our offering of capital equipment

and technology-driven products in Spain; and

• Ortho Organizers, a California-based orthodontics 

manufacturer and distributor.

1 Third quarter 2008 charge related to the Lehman Brothers 
bankruptcy ($0.03 per diluted share after tax) and fourth quarter
2008 restructuring costs ($0.18 per diluted share after tax).

quarksHKnew6  4/14/09  2:47 PM  Page 5

Resiliency, Reinvention and Relevancy
The resiliency of a company during challenging times is 

“Helping Health Happen”

Henry Schein is “helping health happen®” in a number 

largely based on its ability to reinvent itself and become more

of ways, including helping our customers with financing.

relevant to customers. Henry Schein’s continued success will

Through Henry Schein Financial Services, a strategic advantage

come through our commitment to more effectively help our

for our Company, we can help ensure that customers have

customers meet growing practice challenges. 

competitive financing options for their patients and their 

Our mission is to help our customers run more efficient and

profitable practices as they provide patients the highest 

standards of patient care.  By continuously answering our 

customers’ most important question—“How can Henry Schein

help me thrive during this unstable economic time?”—we are

practices, making it easier to purchase equipment and 

technology—driving practice success now and in the future. 

In 2008, we helped more than 11,000 Henry Schein customers

in the United States enhance their practices with financing

options through third parties, at no credit risk to us.  

determined to become even more relevant to the success of

We also are providing value to our customers through 

our customers’ practices.  

our nearly 20,000 proprietary Henry Schein brand products, 

Relevancy begins by listening to our customers. In 2008, 

we launched the inaugural Henry Schein Survey of Healthcare

Practitioners, in which we asked our dental, medical and animal

health customers for their opinions on a number of topics.  

many of which have a leading market share in their respective 

categories. These high-quality products come with the 

Henry Schein Seal of Excellence, which guarantees satisfaction

to our customers.

The number one “top of mind” issue that emerged was that 

We also will continue to meet our commitment to our other

our customers are forced to spend more time managing 

four constituencies. Our supplier partners are relying on us 

practices at the expense of providing patient care (52% 

to develop a trusted relationship with our customers, offering

medical, 42% animal health and 41% dental). Additionally, our 

our suppliers’ products as solutions to practice needs. 

customers remain committed to incorporating new technology

Our investors expect us to take all necessary steps to improve

in their practices, with nearly 9 of 10 customers surveyed 

our organizational efficiency and build market share, so 

saying that technology will play an increasingly important role.

we will continue to grow, be profitable and provide a good 

Environmental consequences also are influencing practices,

return on investment. The more than 12,500 members 

and we saw a sustained commitment to volunteer activity

of Team Schein will be crucial to the reinvention of our

across all three customer groups.

Company if we are to take advantage of the opportunities

“Henry Schein’s 

continued success will come

through our commitment 

to more effectively 

help our customers 

meet growing 

practice challenges.”

resulting from the enormous economic changes we are now

experiencing. And, our Company’s ongoing vitality will enable

us to continue to participate in innovative public-private 

partnerships that give back to society and address important

healthcare issues, many of which become more acute during

times of economic challenge. 

For our efforts through Henry Schein Cares, our global social

responsibility program, we are proud that Henry Schein has

been named “Most Admired” in our industry in FORTUNE’s 

list of the World’s Most Admired Companies, and ranked 

number one in our industry in social responsibility for five 

consecutive years. Through flagship programs such as 

Give Kids A Smile and Healthy Children, Healthy Lifestyles, 

5

quarksHKnew6  4/14/09  2:47 PM  Page 6

The wide range of Henry Schein Cares programs—including (from left to right) Give Kids A Smile, Holiday Cheer for Children, Back to School,

and Healthy Children, Healthy Lifestyles—are helping to enhance healthcare advocacy and education; increase access to care; strengthen 

community wellness programs; and further humanitarian relief and disaster response.

through our core donation program, and through partnerships

There is a growing demand for office-based healthcare 

with other companies, academia, government and non-govern-

services driven by baby boomers and emerging markets, 

mental organizations, we are supporting a wide range of 

as well as the potential that government policy, especially in 

initiatives that enhance healthcare advocacy and education;

the United States, will expand access to care. Henry Schein is 

increase access to care among underserved populations;

well positioned to arrange for customer financing during this 

strengthen community wellness programs and volunteer 

time of limited access to credit. And we remain committed to 

activities; and further humanitarian relief and disaster response.

the five constituencies of our Company’s mosaic of success: 

To continue to expand the impact of our social responsibility 

our customers, supplier partners, investors, Team Schein, 

programs, in 2008 we began the process of creating the 

and society.

Henry Schein Cares Foundation.

Shared Commitment and Optimism  
As we face today’s challenges and opportunities, Henry

Schein’s senior leadership is resolved to take the steps 

necessary to ensure the long-term vitality of our Company, 

and all Team Schein Members are committed to our shared

vision. We share a sense of optimism based on our Company’s

financial strength, values, strong partnerships, ideal markets 

and strategic focus on the future.  

These facts, coupled with our entrepreneurial Team Schein

culture, make our Company more resilient in turbulent times and

position us well to take advantage of emerging opportunities.

Without question, this is a remarkable time—a time that requires

reinvention and increased relevancy for our Company, as well as

consistent expense management—but Henry Schein continues

to be well positioned, and I remain convinced that our best 

years are yet to come. On behalf of our Board of Directors 

and my Team Schein colleagues, we thank you for your 

continued support.

We have an outstanding business and a solid balance sheet.

The markets we serve remain fragmented, with about one-half 

Sincerely,

of them in the hands of smaller competitors. With nearly 

$370 million in cash and equivalents, low debt levels, positive

cash flow and an unused $400 million five-year credit facility, 

we are in a very strong financial position to implement our 

Stanley M. Bergman

strategic plan and to seize new business opportunities, while 

Chairman and Chief Executive Officer

at the same time, we continue to focus on expense reduction

and margin management.

6

quarksHKnew6  4/14/09  2:48 PM  Page 7

EXECUTIVE OFFICERS

EXECUTIVE OFFICERS AND BOARD OF DIRECTORS

Stanley M. Bergman (5) 
Chairman and Chief Executive Officer

Stanley Komaroff
Senior Advisor

Gerald A. Benjamin (5) 
Executive Vice President and 
Chief Administrative Officer

Mark E. Mlotek (5) 
Executive Vice President, 
Corporate Business Development 

James P. Breslawski (5) 
President and Chief Operating Officer

Leonard A. David
Senior Vice President and 
Chief Compliance Officer

James Harding
Senior Vice President and 
Chief Technology Officer

Steven Paladino (5) 
Executive Vice President and 
Chief Financial Officer

Michael Racioppi
Senior Vice President and 
Chief Merchandising Officer

Michael Zack
President, International Group

INDEPENDENT BOARD OF DIRECTORS

Barry J. Alperin (1) (2) (3) 
Retired Vice Chairman, Hasbro, Inc.

Philip A. Laskawy (1) (3) (4) 
Retired Chairman, Ernst & Young LLP

Paul Brons (4) 
Former Member, Board of Management, 
Akzo Nobel, N.V.

Margaret A. Hamburg, M.D. (4)
Former Assistant Secretary for Planning and
Evaluation, U.S. Department of Health and 
Human Services; Former Commissioner of 
Health for the City of New York

Donald J. Kabat (1) (2) 
Retired Partner, Accenture, Ltd.

Karyn Mashima (4)
Private Consultant; Former Senior Vice President, 
Strategy and Technology, Avaya

Norman S. Matthews (2) (4) 
Former President, Federated 
Department Stores, Inc.

Louis W. Sullivan, M.D. (3) (4) 
Former U.S. Secretary of Health and 
Human Services; Founding Dean, 
Director and President Emeritus of the 
Morehouse School of Medicine

(1) Member Audit Committee

(3) Member Nominating and Governance Committee

(5) Member Board of Directors

(2) Member Compensation Committee

(4) Member Strategic Advisory Committee

7

quarksHKnew6  4/14/09  2:48 PM  Page 8

NON-GAAP DISCLOSURES

The following table sets forth, for the periods indicated, a reconciliation of operating income and income from continuing operations adjusted to reflect the effects of discontinued
operations, as reported to adjusted operating income and adjusted income from continuing operations. The diluted earnings from continuing operations per share and weighted-average
common shares outstanding information reflects a two-for-one stock split effected in the form of a dividend that became effective on February 28, 2005.

Years ended

December 27, 
2008

December 25, 
2004

December 27,
2003

(in thousands, except per share data)

De

Operating income, as reported

$ 419,603 

$  191,949 

$ 217,432 

Adjustments:

Restructuring costs (1)

One-time charge related to influenza vaccine contract (2)

Adjusted operating income

Adjusted operating margin

23,240   

- 

442,843 

6.9%

-   

13,246   

205,195 

5.4%

-

-   

217,432  

6.8%

Income from continuing operations, as reported

251,011 

114,129 

128,759  

Adjustments, net of tax:

Restructuring costs (1)

One-time charge related to influenza vaccine contract (2)

Loss related to the Lehman Brothers bankruptcy (3)

15,991   

- 

3,045 

-   

8,358   

-   

-

-   

-   

Adjusted income from continuing operations

$ 270,047 

$  122,487 

$ 128,305 

Diluted earnings from continuing operations per share:

As reported

Adjusted

$

2.75 

2.96 

$

1.29 

1.39 

$

1.45 

1.44 

Diluted weighted-average common shares outstanding:

91,221 

89,646 

89,099

USE OF NON-GAAP MEASURES:
The above information includes financial measures that are not calculated and presented in accordance with accounting principles generally accepted in the United States (“GAAP”).
The above table reconciles operating income, income from continuing operations and diluted earnings from continuing operations per share, our most directly comparable measure
calculated and presented in accordance with GAAP, to comparable amounts as adjusted to eliminate the effect of one-time items.

We eliminated the effect of such one-time items to assist in evaluating the underlying operational performance of our business, excluding such one-time items, over the periods 
presented. We believe that this presentation is appropriate and facilitates such an evaluation by us, investors and analysts. These measures should be considered supplemental to,
and not a substitute for or superior to, financial measures calculated in accordance with GAAP.

NOTES:

(1) During 2008, we recorded restructuring costs of $23.4 million pre-tax ($16.0 million post-tax). The effect that this charge had on earnings per diluted share 

from continuing operations for the year ended December 27, 2008 was ($0.18).

(2) During 2004, we recorded a non-recurring $13.2 million pre-tax ($8.4 million post-tax) charge related to the Fluvirin® contract with Chiron Corporation.

The effect that this charge had on earnings per diluted share from continuing operations for the year ended December 25, 2004 was ($0.10). Excluding this charge,
our earnings per diluted share from continuing operations for 2004 was $1.39.

(3) During 2008, we recorded a charge related to the Lehman Brothers bankruptcy of $4.5 million pre-tax ($3.0 million post-tax). The effect that this charge had on 

earnings per diluted share from continuing operations for the year ended December 27, 2008 was ($0.03).

8

Henry Schein, Inc.

135 Duryea Road

Melville, New York  11747

U.S.A.

(631) 843-5500

www.henryschein.com